Rick Simpson Oil (RSO) in Pawnee County, Kansas: The Complete Guide by OilWell Cannabis

Why Pawnee County Deserves Better Cannabis Education

In Pawnee County, where the winds sweep across the plains and the community values hard work and honest answers, we know that health decisions aren’t made lightly. Whether you’re dealing with chronic pain, supporting a loved one through chemotherapy, or searching for alternatives when conventional medicine falls short, you deserve clear, science-backed information—not hype, not guesswork, and certainly not snake oil.

That’s why we’re bringing our Houston-made, lab-tested Rick Simpson Oil (RSO) formulas to Pawnee County. But more importantly, we’re bringing the full story—what RSO actually is, what it can and can’t do, and how our modern, evidence-informed approach makes it safer and more effective than ever before.

Rick Simpson Oil: The Origin Story and Why It Matters in Pawnee County

Who Was Rick Simpson?

Rick Simpson wasn’t a doctor, scientist, or medical researcher. He was a power engineer from Nova Scotia who turned to cannabis after conventional medicine failed him. In 1997, Simpson suffered a serious head injury at work, leaving him with persistent tinnitus, dizziness, and post-concussion symptoms that no prescription could resolve. When he asked his doctor about cannabis, he was refused.

Simpson’s story took a dramatic turn in 2003 when he claimed that concentrated cannabis oil removed three bumps on his arm that his doctor diagnosed as basal cell carcinoma. No independent medical verification exists, and no biopsy or clinical follow-up was documented. Yet this personal experience became the foundation of Rick Simpson Oil (RSO) and inspired a global movement.

The Crusade That Changed Cannabis

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil. He gave it away for free to cancer patients and others in his community, charging nothing. He claimed to help people with conditions ranging from cancer and chronic pain to diabetes, infections, glaucoma, arthritis, depression, and insomnia.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, which framed his work as a grassroots challenge to pharmaceutical and governmental interests. The film became foundational in cannabis communities worldwide, including here in Kansas.

The Traditional RSO Protocol: What It Was and Why It Needed to Evolve

Simpson’s core treatment recommendation was a 60-gram, 90-day oral protocol designed to deliver concentrated cannabis oil. Here’s what that looked like:

• Week 1: Start with a dose the size of half a grain of rice (about 10-15 mg) three times daily.
• Weeks 2-5: Gradually increase the dose to about 1 gram per day.
• Weeks 5-12: Maintain 1 gram per day until the full 60 grams were consumed.
• Administration: Primarily oral (sublingual or swallowed), with topical application for skin cancers.
• Post-protocol: Maintenance dosing of 1-2 grams per month indefinitely.

This protocol was never validated through clinical trials. It was based on Simpson’s personal experience and anecdotal observations. Several critical considerations apply:

• No controlled trial validation: There are no published randomized controlled trials or well-documented case series evaluating this protocol for any condition.
• Unstandardized material: The 60-gram quantity assumed a single-strain, THC-dominant extract with no standardized potency.
• Very high THC exposure: At peak dosing, patients consumed approximately 600-900 mg of delta-9 THC daily—far exceeding anything studied in controlled clinical settings.
• Real risks at these doses: Consuming 600-900 mg of THC daily carries serious risks, including severe intoxication, impairment, anxiety, panic, tachycardia, and cannabis use disorder.
• Oncology context: Patients with active cancer are medically complex. Using unregulated cannabis oil as a primary treatment instead of proven therapies can cause real harm.

Traditional RSO: What It Actually Was (And Why It Was Problematic)

Traditional RSO was defined by Simpson’s method and materials:

• Source material: High-THC, indica-dominant cannabis strains with no standardization.
• Extraction solvent: Naphtha (a petroleum-based solvent) or 99% isopropyl alcohol—neither food-grade.
• Extraction process: Plant material was soaked in solvent, agitated, filtered, and the solvent was evaporated in a rice cooker, converting all THCa to THC and destroying terpenes.
• Appearance: Nearly black, thick, tar-like oil with a strong cannabis odor and possible solvent-residual smell.
• Cannabinoid profile: Fully decarboxylated, THC-dominant (60-90% THC), with minor cannabinoids at natural ratios—uncontrolled and unmeasured.
• Terpene content: Minimal to none due to solvent and heat destruction.
• Standardization and testing: None. Every batch was different with no lab verification.
• Residual solvent risk: Significant risk of harmful residues from naphtha or isopropyl alcohol.

The Evidence Record: What Simpson Claimed vs. What Science Actually Shows

Simpson claimed RSO could cure cancer and many other diseases. Let’s evaluate those claims against the actual evidence base.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or suppressing that conversation. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. The term “RSO” remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment instead of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative medicine literature.

Institutional Positions

• National Cancer Institute (NCI): Acknowledges cannabinoid anticancer research in laboratory and animal models but does not endorse cannabis as a cancer treatment.
• Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. Approved cannabinoid-related products are for specific indications like epilepsy and chemotherapy-related nausea.
• Health Canada: Has never approved RSO or cannabis oil as a cancer cure.
• National Center for Complementary and Integrative Health (NCCIH): States the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cures.

How OilWell Cannabis Evolved the RSO Concept for Pawnee County

The OilWell Story: From a Dog Named Bentley to Modern RSO

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin’s journey began in McAllen, Texas, along the border with Mexico—a region marked by economic challenges and cartel violence. His early experiences taught him resilience and the value of community.

The company’s origin story begins with a dog named Bentley. When Bentley became paralyzed and faced euthanasia, Colin refused to give up. He discovered CBD and created a golden paste that gave Bentley his mobility back. Bentley lived another ten years, and during that time, Colin developed specialized cannabis formulas for every condition Bentley faced—neurodegeneration, dementia, glaucoma, and arthritis.

This experience taught Colin that single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. That knowledge became the foundation of OilWell’s approach.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction, using cannabinoid knowledge to quit Xanax cold turkey. The Peace Gummies formula was born from his own midnight experiments during benzo withdrawal.

The OilWell RSO Philosophy: Four Core Principles for Pawnee County

1. Accessibility Over Gatekeeping: No medical card is required. Anyone age 21 or older can purchase. We ship nationwide and internationally to customers who verify local legality.
2. Patient-Controlled Potency: THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency.
3. Open-Source Formulas: We publish our complete formulas so that anyone who can’t afford our products can source ingredients and make their own version.
4. Evidence-Informed, Not Evidence-Overstating: We commit to honest education about what the science actually says.

Farm Bill Compliance and the THCa Legal Framework

Our RSO products are legal under the 2018 Farm Bill, which legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight.

• Our sublingual oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle—well under the 0.3% threshold.
• THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC, making it legal at the point of sale.
• You can decarboxylate THCa at home by heating the oil at 260°F (125°C) for 45-60 minutes, converting 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this yields approximately 1,405 mg of total delta-9 THC—giving you psychoactive potency comparable to traditional RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory or as a full-potency psychoactive cannabinoid product, depending on how you choose to use it.

Open-Source Formulas: Why We Publish Everything

We publish our complete RSO formulas—every cannabinoid, every milligram amount, every percentage—so that if you can’t afford our products, you can source the ingredients and make your own version. This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. We sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

Here’s the actual CBD golden paste recipe that saved Bentley’s life, published for free so that any pet owner facing a similar crisis can make it themselves:

CBD Golden Paste Recipe for Pets

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water: In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste (about 7-10 minutes). Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper: Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store: Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage: Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated, leaving patients with no choice about psychoactivity. Our sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form, creating three distinct usage options:

1. Raw, No Heat: All 1,500 mg stays as THCa—completely non-psychoactive. This option is compatible with work, driving, and daytime use with zero impairment.
2. Fully Activated, Home Decarboxylation: Heating the oil at 260°F (125°C) for 45-60 minutes converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this yields approximately 1,405 mg of total delta-9 THC for full psychoactive potency.
3. Vape, Auto-Decarboxylation: The RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation for fast relief.

The conversion chemistry: 1 mg of THCa converts to approximately 0.877 mg of delta-9 THC after decarboxylation.

This design puts the potency decision entirely in your hands.

Solvent-Free Production: Why It Matters for Pawnee County

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Our products are formulated blends of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No solvents are present in the finished product.

We use organic MCT oil (medium-chain triglycerides) as the carrier base, which facilitates cannabinoid absorption and provides a neutral taste profile. Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request.

The OilWell RSO Formulas: What’s Inside and Why It Matters

RSO Sublingual Oil: The Complete Formula

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle with graduated dropper for precise dosing in 0.1 mL increments
• Active cannabinoids per mL: 553 mg
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)

RSO Vape Cartridge: Fast Relief When You Need It

• Live Terpenes: 5%+
• Format: 1-gram cartridge with 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Auto-decarboxylation: THCa converts to delta-9 THC at vaping temperature

Terpene Profile: Why We Include Live Terpenes

Both products feature the same seven-terpene profile:

• Limonene: Citrus-bright, mood-enhancing
• Myrcene: Earthy, relaxing
• Caryophyllene (β-caryophyllene): Pepper/spice, CB2 agonist
• Pinene: Forest-fresh, clarifying
• Linalool: Floral, lavender-like, calming
• Humulene: Earthy, woody, anti-inflammatory
• Terpinolene: Piney, fruity, complex

Terpenes are more than just flavor and aroma. They may influence absorption, effect, and tolerability, even if robust human clinical proof of cannabis-specific entourage effects remains limited.

When to Use Each Format: A Guide for Pawnee County Lifestyles

Condition-Specific Usage Context for Pawnee County Residents

Important Disclaimer: The following usage contexts are informed by cannabinoid research and OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: Delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
  • At 2.0 mL: Delivers 50 mg CBN—the dosage level investigated in recent sleep literature
  • At 1.0 mL: Delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General Titration Principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and Accessibility: How Pawnee County Residents Can Get OilWell RSO

We operate the only same-day RSO delivery system in Houston, but we also ship nationwide and internationally.

Nationwide Shipping

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

International Shipping

We ship internationally to jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

• Full documentation provided for customs purposes
• Certificates of Analysis (COAs) included
• Customer responsibility: Verify legality in your jurisdiction and accept all customs and legal risk
• Contact us: (832) 416-2816 or [email protected]

The Science Behind OilWell RSO: What the Evidence Actually Says

Research Method and Evidence Weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse.

Institutional Baseline from NIH and Related Sources

• Strongest established evidence: Rare epilepsies, chemotherapy-related nausea and vomiting, appetite or weight-loss indications associated with HIV/AIDS.
• Modest evidence: Chronic pain and multiple-sclerosis-related symptoms.
• Safety concerns: Impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy.

Cannabinoid Evidence Profiles

CBD (Cannabidiol)

• Best supported: Purified CBD has the most credible human evidence in seizure disorders.
• Anxiety research: Statistically significant anxiolytic signal, but clinical sample remains limited.
• Pain research: Promising but heterogeneous, with trial quality and consistency still limiting confidence.
• Sleep research: Literature remains methodologically weak, with many studies relying on nonvalidated subjective measures.
• Safety concerns: Liver enzyme elevation, possible drug-induced liver injury, diarrhea, sleepiness, appetite change, mood effects, drug-drug interactions.

CBG (Cannabigerol)

• Evidence profile: Mostly review-level and preclinical; human evidence sparse.
• Pharmacology: Biosynthetic precursor to several major cannabinoids with distinct interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling.
• Potential research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity.
• Caution: Already being sold commercially while evidence base remains thin.

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, less clinically characterized than delta-9 THC.
• Comparative pharmacology: Broadly similar to delta-9 THC but less potent.
• Public-health literature: Much evidence still dominated by animal studies, product chemistry, use reports, and public-health concerns.
• Manufacturing context: Commercial interest tied to greater stability and easier synthesis relative to naturally scarce plant levels.

THCa (Tetrahydrocannabinolic Acid)

• Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence.
• What it is: Acidic precursor of THC; decarboxylates into THC during heating and can change over time during storage.
• Psychoactivity: Non-psychoactive in its acidic form; psychoactive when decarboxylated.
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities.

Delta-9 THC

• Evidence profile: Strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden.
• Best supported: Chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, some multiple-sclerosis- and pain-related outcomes.
• Pain evidence: May provide short-term pain benefit but increases dizziness, sedation, nausea, and treatment discontinuation.
• Safety concerns: Anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns.

CBN (Cannabinol)

• Evidence profile: Weak human evidence; marketing has moved ahead of the data.
• What it’s marketed for: Sleep and sedation.
• Sleep evidence: No clinical trials using validated sleep questionnaires or formal polysomnography substantiate strong sleep-promoting claims.
• Chemical context: Downstream cannabinoid degradation product; often discussed in aging or oxidized cannabis chemistry contexts.

CBC (Cannabichromene)

• Evidence profile: Emerging, intriguing, still overwhelmingly preclinical or review-based.
• Pharmacology: Distinct from better-known cannabinoids with antinociceptive, antibacterial, and anti-seizure research targets.
• Safety caveat: Over-the-counter CBC products already being sold despite little evidence establishing clinical efficacy or safety.

Terpene Evidence Profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models.

Limonene

• Evidence profile: Largely review and preclinical.
• Potential activity: Antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory.
• Safety note: Oxidation products are clinically relevant contact allergens.

Myrcene

• Evidence profile: Mostly preclinical, very limited human evidence.
• Research summary: Anxiolytic, antioxidant, anti-inflammatory, and analgesic properties.
• Interpretation caution: Often invoked as a proven sedating terpene; stronger claim than human evidence supports.

Caryophyllene (β-Caryophyllene)

• Evidence profile: Mechanistically interesting due to direct CB2 receptor agonism, but mostly preclinical.
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective.

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: Antioxidant, anti-inflammatory, neuroprotective signals.
• Interpretation caution: Claims about memory improvement or attention sharpening remain hypotheses.

Linalool

• Evidence profile: Substantial preclinical interest, limited direct clinical confirmation.
• Research summary: Stress, mood, and brain-health pharmacology.
• Safety note: Oxidized linalool hydroperoxides are recognized allergens.

Humulene

• Evidence profile: Translationally interesting, still early.
• Scoping-review findings: Broad preclinical evidence for anti-inflammatory and other biologic effects.

Terpinolene

• Evidence profile: Least clinically characterized terpene in this list.
• Systematic-review findings: Range of reported biological effects, but evidence base still dominated by in silico, in vitro, and animal studies.

Common Overstatements to Avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: The specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.
• Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for Pawnee County Residents

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully.

Why OilWell RSO Is Different: A Comparison for Pawnee County

The OilWell Promise to Pawnee County

OilWell Cannabis is more than a brand—it’s a promise to deliver the best, most thoughtful cannabis products available. We’re not here to follow trends. We’re here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

If you’re in Pawnee County and you’re considering RSO, we want you to have the full story. That’s why we’ve created this guide—so you can make an informed decision based on real science, not hype. Whether you choose to purchase our products or make your own using our open-source formulas, we’re here to support you with honest, transparent information.

For more information or to place an order, visit OilWell CBD or call us at (832) 416-2816. We’re proud to serve Pawnee County and look forward to being part of your wellness journey.